First Light reports 2.85% Organogenesis stake
Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Organogenesis Holdings Inc. received an amended Schedule 13G from institutional investor First Light Asset Management, LLC and its control person, Mathew P. Arens, reporting their current ownership in the company’s common stock.
The filing shows First Light Asset Management may be deemed to beneficially own 3,611,616 shares, representing 2.85% of Organogenesis’ common stock. Mathew P. Arens may be deemed to beneficially own 3,888,816 shares, or 3.06% of the class, including 231,000 shares he holds directly and additional shares through joint and advised accounts.
The reporting persons certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Organogenesis. Because each now reports ownership below 5% of the outstanding shares, the filing confirms they are no longer large (5%+) shareholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Schedule 13G/A filing report for Organogenesis (ORGO)?
What is Mathew P. Arens’ reported ownership in Organogenesis (ORGO)?
Why did First Light and Mathew P. Arens file an amended Schedule 13G for ORGO?
Do First Light and Mathew P. Arens seek to influence control of Organogenesis (ORGO)?
AI-generated analysis. How Rhea-AI works. Not financial advice.